Go Pro
NASDAQ:TRAX

First Tracks Biotherapeutics Q2 2026 Earnings Report

$34.60 -1.23 (-3.42%)
As of 02:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

First Tracks Biotherapeutics EPS Results

Actual EPS
-$0.95
Consensus EPS
-$0.74
Beat/Miss
Missed by -$0.21
One Year Ago EPS
N/A

First Tracks Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

First Tracks Biotherapeutics Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
4:00PM ET

First Tracks Biotherapeutics Earnings Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
First Tracks Biotherapeutics Inc (TRAX)
See More First Tracks Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like First Tracks Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on First Tracks Biotherapeutics and other key companies, straight to your email.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics (NASDAQ:TRAX) is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

View First Tracks Biotherapeutics Profile